AbbVie gains attention as healthcare rotation highlights Skyrizi, Rinvoq, immunology growth, and portfolio strength beyond ...

JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.

AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...

Looking for the latest dividend stock opportunities in July 2026? Click to which dividend stocks may be worth snagging now to up your passive income.

AbbVie ABBV is set to report first-quarter 2026 earnings on April 29, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.78 billion and $2.69 per share, ...

Cosentyx (secukinumab) and Humira (adalimumab) are prescription drugs used to treat similar conditions. Both drugs come as subcutaneous injections, however, Cosentyx may also be given as an ...

The approval of the interchangeable designation was supported by data from a randomized, double-blind phase 4 trial (ClinicalTrials.gov Identifier: NCT05510063) that assessed the pharmacokinetics, ...

Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms.

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs. The FDA has granted interchangeability designation to Celltrion’s Yuflyma ...

Please provide your email address to receive an email when new articles are posted on . Celltrion’s Yuflyma is a high concentration, citrate-free formulation of adalimumab. It is the ninth Humira ...

A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a ...